Objective: The vasopressor effect of arginine vasopressin, a mixed V 1a /V 2 receptor (V 1a R/V 2 R) agonist, is mediated through the V 1a R. Because V 2 R stimulation may aggravate sepsis-induced vasodilation, fluid accumulation, and microvascular thrombosis, a higher V 1a R vs. V 2 R selectivity might be advantageous. The objective of this study was to elucidate the effects of a first-line therapy with the selective V 1a R agonist Phe 2 -Orn 8 -Vasotocin vs. arginine vasopressin or norepinephrine on cardiopulmonary hemodynamics and organ function in ovine septic shock. Design: Randomized controlled laboratory experiment. Setting: University animal research facility. Subjects: Twenty-four chronically instrumented sheep. Interventions: After the onset of fecal peritonitis-induced septic shock (mean arterial pressure <60 mm Hg), sheep were randomly assigned to receive first-line treatment with Phe 2 -Orn 8 -Vasotocin (0.05 g⅐kg ؊1 ⅐h ؊1 ), arginine vasopressin (0.05 g⅐kg ؊1 ⅐h ؊1 ), or normal saline (each n ‫؍‬ 8). In all groups, open-label norepinephrine was additionally titrated up to 1 g⅐kg ؊1 ⅐min ؊1 to maintain mean arterial pressure at 70 ؎ 5 mm Hg, if necessary. Measurements and Main Results: Compared with single norepinephrine therapy, the selective V 1a R agonist Phe 2 -Orn 8 -Vasotocin reduced norepinephrine requirements (2-6 hrs: p < .05 each) and fluid accumulation (p ‫؍‬ .043). In addition, mean arterial pressure (6 -10 hrs: p < .05 each), pulmonary gas exchange (8 -10 hrs: p < .05 each), and global oxygen transport (10 hrs: p < .05 each) were improved by Phe 2 -Orn 8 -Vasotocin vs. both other groups. Despite similar preload left ventricular stroke work index was higher in Phe 2 -Orn 8 -Vasotocin-than in arginine vasopressin-treated animals (10 hrs: p ‫؍‬ .02). Metabolic dysfunction (base excess, lactate concentrations) and renal dysfunction (urinary output, creatinine clearance) were attenuated by Phe 2 -Orn 8 -Vasotocin infusion when compared with arginine vasopressin and single norepinephrine therapy. Immunohistochemical analyses of lung tissue revealed higher hemeoxygenase-1 and lower 3-nitrotyrosine concentrations in Phe 2 -Orn 8 -Vasotocin-treated animals vs. both other groups (p < .05 each). In addition, the selective V 1a R agonist Phe 2 -Orn 8 -Vasotocin slightly prolonged survival when compared with arginine vasopressin (p ‫؍‬ .01) and standard treatment with norepinephrine (p ‫؍‬ .003). Conclusions: Selective V 1a R agonism appears to be superior to the V 1a R/V 2 R agonist arginine vasopressin and single norepinephrine infusion for hemodynamic support in septic shock. (Crit Care Med 2011; 39:119 -125)
T he Surviving Sepsis Campaign suggests that "arginine vasopressin (AVP) may be subsequently added to norepinephrine" in volume-and catecholaminerefractory septic shock (1) . In the randomized, controlled multicenter Vasopressin and Septic Shock Trial (VASST), however, AVP failed to reduce overall mortality as compared with norepinephrine (2) .
Notably, AVP and the synthetic longacting vasopressin analog terlipressin represent mixed V 1a /V 2 receptor (V 1a R/ V 2 R) agonists with a selectivity of 1:1 and 2.2:1 for the V 1a R, respectively. Whereas activation of vascular V 1a Rs contributes to vasoconstriction (3, 4) , stimulation of extrarenal (endothelial) V 2 Rs may aggravate sepsis-induced vasodilation (4, 5) , fluid accumulation (6) , leukocyte rolling (7) , and microvascular thrombosis (8) . Therefore, a higher selectivity for the V 1a R vs. the V 2 R could be advantageous. This assumption is supported by recent experimental (9) and clinical studies (10) reporting a superiority of terlipressin over AVP in stabilizing cardiovascular hemodynamics in septic shock. A highly selective V 1a R agonist, however, has not yet been investigated in the setting of septic shock.
We hypothesized that first-line therapy with the highly selective V 1a R agonist Phe 2 -Orn 8 -Vasotocin (POV), supplemented with open-label norepinephrine, is more effective in restoring mean arterial pressure (MAP) and organ functions than the first-line therapy with AVP or norepinephrine alone (NE). Therefore, the present randomized controlled laboratory experiment was designed to elucidate the effects of these treatment strategies on cardiopulmonary hemodynamics, global oxygen transport, acid-base balance, mes-enteric blood flow, nitrosative stress, and mortality. The study hypothesis was tested in an established ovine model of fulminant septic shock resulting from generalized fecal peritonitis (9, 11) .
MATERIALS AND METHODS

Instrumentation and Surgical Procedures.
After approval by the Local Animal Research Committee, 24 female sheep were anesthetized, mechanically ventilated, and instrumented for chronic hemodynamic monitoring (femoral arterial line, pulmonary artery catheter, and urinary bladder catheter) using an established protocol (9, 11) . Details on the instrumentation, surgical procedures, and measurements are provided in the supplemental data (see Supplemental Digital Content 1, http://links.lww.com/CCM/A179).
Experimental Protocol. After baseline (BL) measurements, autologous feces were injected into the peritoneal cavity through an intraperitoneal suction catheter. When septic shock had developed ("shock time" [ST]; defined as MAP Ͻ60 mm Hg), a second set of measurements was performed. The animals were then randomly assigned to one of the three study groups (n ϭ 8 (9) .
Hemodynamic Measurements, Blood Gas, and Laboratory Analyses. Hemodynamic measurements included heart rate, MAP and mean pulmonary arterial pressure, central venous (central venous pressure), and pulmonary arterial occlusion pressure as well as cardiac output. Cardiac index, systemic vascular resistance index, right and left ventricular stroke work indices (LVSWI), oxygen delivery, and consumption index as well as oxygen extrac-tion rate were calculated using standard equations (12) . Hemodynamic measurements, arterial and mixed venous blood gas analyses were performed every hour after ST and laboratory analyses only at BL, ST, 4 hrs, and 8 hrs. Cumulative net fluid balance was calculated by subtracting urine output from fluid input.
Immunohistochemical Analyses. After death, lung tissue samples were immediately stored for immunohistochemical analyses. Pulmonary concentrations of hemeoxygenase-1 (StressXpress Human HO-1 ELISA Kit; NE, norepinephrine, AVP, arginine vasopressin; POV, selective V 1a receptor agonist; HR, heart rate; CI, cardiac index; SVRI, systemic vascular resistance index; CVP, central venous pressure; LVSWI, left ventricular stroke work index; RVSWI, right ventricular stroke work index; MPAP, mean pulmonary arterial pressure; PAOP, pulmonary arterial occlusion pressure; Qma, mesenteric arterial blood flow; BL, baseline; ST, shock time.
Data are represented as median with interquartile range ͓25th; 75th͔. a p Ͻ .05 vs. ST; b p Ͻ .05 vs. AVP; c p Ͻ .05 vs. BL; d p Ͻ .05 vs. NE; n ϭ 8 per group. NE: n ϭ 7 at 8 hrs and 10 hrs; AVP: n ϭ 6 at 10 hrs; POV: n ϭ 8 each.
Stressgen Bioreagents, Ann Arbor, MI) and 3-nitrotyrosine (Hycult biotechnology 3-nitrotyrosine solid-phase ELISA; Cell Sciences, Canton, MA) were determined as described previously (13, 14) .
Statistical Analyses. Sigma Stat 3.1 software (Systat Software, Inc, San Jose, CA) was used for statistical analyses. Analysis of variance on rank methodologies appropriate for nonnormally distributed variables with repeated measures across time for each animal were used. Each variable was analyzed separately for differences among groups, differences across time, and for group-by-time interaction. After confirming the significance of different group effects over time, post hoc pairwise comparisons among groups were performed using the Student-Newman-Keuls procedure to adjust for the elevated false-positive rate found otherwise in multiple testings. After 10 hrs, no statistical analyses were performed, because the small number of animals alive in the AVP and NE group did not allow reliable testing any more. Survival time was analyzed using the Kaplan-Meier method and the log-rank test. Group differences were analyzed by pairwise multiple comparisons using the Holm-Sidak test. Data are expressed as median with interquartile range (25th; 75th). Differences were considered as statistically significant when p was Ͻ.05.
RESULTS
Baseline Characteristics. There were no differences among study groups in any of the investigated variables at BL and ST. Mean body weight (39 kg [34; 41] ) and time to onset of septic shock (7 hrs [6; 9]) did not differ among groups.
Cardiopulmonary Hemodynamics and Mesenteric Blood Flow. Changes in cardiopulmonary variables are presented in Figures 1 and 2 and Table 1 . Septic shock was characterized by decreases in MAP, systemic vascular resistance index, and LVSWI (ST: p Յ .001 vs. BL each). Cardiac index, mean pulmonary arterial pressure, and pulmonary arterial occlusion pressure increased as compared with BL (ST: p Ͻ .05 vs. BL each). All three treatment strategies maintained MAP within the target range (70 Ϯ 5 mm Hg) for the first 4 hrs (p Ͻ .01 vs. ST each; Fig. 1 ) and increased LVSWI (4 hrs: p Ͻ .05 vs. ST each; Table 1 ). After the dose limit for NE had been reached, MAP fell below ST values in the NE and AVP group (8 -10 hrs: p Ͻ .05 vs. ST each). In contrast, MAP in the POV group was within the target range until 8 hrs and significantly higher than in both other groups (6 -10 hrs). Accordingly, systemic vascular resistance index was higher in the POV group than in both other groups (8 hrs: p Ͻ .05 each; Table 1 ). Cumulative NE requirements were lower in POVtreated than in NE-treated animals (2-6 hrs: p Ͻ .05 each; Fig. 2A ).
Myocardial dysfunction was evidenced by a decrease in LVSWI in all groups after 4 hrs. Despite similar pulmonary arterial occlusion pressures, LVSWI was lower in AVP-treated as compared with POVtreated animals (10h: p ϭ .02; Table 1 ). Heart rate was reduced after AVP infusion as compared with POV (8 hrs: p ϭ .01). Central venous pressure and pulmonary arterial occlusion pressure, as surrogate variables of cardiac filling pressures, increased over time without differences among groups (Table 1) . Mesenteric blood flow decreased in all groups (10 hrs: p Ͻ .05 vs. ST each; Table 1 ) without statistical differences among groups.
Pulmonary Gas Exchange and Global Oxygen Transport. POV treatment was associated with higher PaO 2 /FIO 2 ratios when compared with the AVP group from 6 to 10 hrs and vs. NE treatment alone from 8 to 10 hrs (p Ͻ .05 each; Fig. 3A ). In addition, POV led to higher systemic oxygen delivery indexes, mixed venous oxygen saturations, and lower systemic oxygen extraction rates than in both other groups (10 hrs: p Ͻ .05 each; Table 2 ; Fig. 3B ).
Capillary Leakage. Septic shock was characterized by a marked decrease in plasma protein concentrations (p Ͻ .001 vs. BL each) that progressed over time (8 hrs: p Ͻ .001 vs. ST each; Table 3 ). Plasma protein concentration was higher after POV treatment as compared with the NE group (8 hrs: p ϭ .03). In addition, cumulative net fluid balance was lower in the POV than in the NE group (p ϭ .043; Fig. 2B ). Notably, there were no differences in hematocrit and the total amounts of fluids administered among groups (Tables 2 and 3) .
Metabolic Changes. Septic shock was associated with decreases in arterial pH (p Ͻ .01 vs. BL each) and base excess (p Ͻ .001 vs. BL each) as well as increases in arterial lactate concentrations (p Ͻ .05 vs. BL each) in all groups ( Table 2 ). Whereas these metabolic changes progressed in AVP-and sole NE-treated animals during the observation period, POV treatment led to lower lactate concentrations (8 hrs: p Ͻ .05 vs. AVP and NE) and less negative arterial base excess values (4 hrs: p ϭ .04 vs. AVP). There were no differences in plasma chloride concentrations among groups ( Table 2) .
Laboratory Variables of Organ Function. POV treatment was characterized by a higher aspartate aminotransferase activity compared with the AVP group (8 hrs: p ϭ .048). Lactate dehydrogenase activity and plasma bilirubin concentration did not differ among groups. Renal dysfunction was evidenced by a progressive decrease in urine output and creati-nine clearance in all groups. POV infusion was associated with a higher creatinine clearance (4 hrs: p ϭ .008; Fig.  4 ) and a higher urine output (4 hrs: p ϭ .004) than sole NE infusion. Laboratory variables of organ function are depicted in Table 3 .
Immunohistochemical Analyses. Immunohistochemical analyses of lung tissue revealed an increase in hemeoxygenase-1 concentration (p ϭ .02 vs. NE and p ϭ .048 vs. AVP; Fig. 5A ) as well as a decrease in 3-nitrotyrosine concentrations (p ϭ .03 vs. NE and p ϭ .048 vs. AVP; Fig. 5B ) in the POV group as compared with both other groups.
Survival Time. All animals died within 15 hrs after ST (Fig. 6 ). POV-treated an-imals had a longer survival time (13.0 hrs [11.5; 14.5] ) than animals that received AVP (10.5 hrs [9.0; 12.0]; p ϭ .01) or sole NE (10.5 hrs [10.0; 11.0]; p ϭ .003), respectively. There were no significant differences in survival time between the AVP and NE groups (p ϭ .55).
DISCUSSION
The major findings of the present study are that first-line therapy with the highly selective V 1a R agonist POV 1) stabilized MAP more effectively and reduced cumulative NE requirements; 2) resulted in a less positive net fluid balance; 3) attenuated pulmonary dysfunction and maintained oxygen delivery more effectively; 4) attenuated metabolic dysfunction; 5) limited pulmonary injury secondary to nitrosative stress; and 6) slightly prolonged survival in early volumeresuscitated, hyperdynamic ovine septic shock as compared with first-line AVP and standard treatment with NE.
In contrast to previous studies (9, (15) (16) (17) (18) , low-dose infusion of AVP did not reveal significant advantages over sole NE with respect to hemodynamic stabilization and NE requirements in the present study. However, it has to be taken into consideration that there was no source control and antibiotic therapy in the present study. In addition, the AVP dose of 0.05 g⅐kg Ϫ1 ⅐h Ϫ1 (equivalent to 0.5 mU⅐kg Ϫ1 ⅐min Ϫ1 or 0.035 U⅐min Ϫ1 in a 70-kg patient) might have been insufficient for the fulminant injury in our model (100% mortality within 15 hrs). This assumption may be in harmony with the observation made in the VASST study that AVP reduced mortality in less severe septic shock but not in the more severe septic shock group (2) . In this context, Torgersen et al (19) recently reported that in patients with sepsis-induced vasodilatory shock, a supplementary infusion of 0.067 U⅐min Ϫ1 AVP was more effective in restoring MAP and reducing NE requirements than the recommended low dose of 0.033 U⅐min Ϫ1 .
Because the vasopressin analog POV has a similar potency as AVP (20) , it was administered in an equivalent dose. However, the selectivity of POV for the V 1a R vs. the V 2 R is Ͼ220 times higher than AVP (21) . This probably explains that POV not only increased MAP as compared with both other groups, but also kept MAP within the target range for a longer time period (8 hrs vs. 4 hrs). In other words, as a result of the lower selectivity, a higher dose of AVP than recommended might have been necessary to achieve the effects of POV.
The decrease in global oxygen transport secondary to a reduction in cardiac index is a common side effect of vasopressor agents (22, 23) . In the present study, septic myocardial dysfunction was attenuated in POV-as compared to AVPtreated animals, as indicated by a higher LVSWI for a given left ventricular filling pressure. Interestingly, the selective V 1 R agonist POV was associated with increases in mixed venous oxygen saturation and lower systemic oxygen extraction rates than in the AVP and NE group. In this context, it is important to exclude a pathologic oxygen supply dependency, which is characterized by a fall in oxygen consumption in dependency of a decreased oxygen delivery (12) . POV infusion, however, was linked to higher systemic oxygen delivery indices and lower arterial lactate concentrations than in both other groups.
Possibly as a result of early, aggressive fluid resuscitation, neither AVP nor POV additionally impaired mesenteric blood flow beyond the changes caused by sole NE. This assumption is supported by the findings of Asfar et al (24, 25) showing that terlipressin infusion after effective volume resuscitation in rats improved splanchnic blood flow but was deleterious in the absence of appropriate fluid substitution. Accordingly, it appears essential that vasopressin analogs are not given in the presence of hypovolemia (1) .
Notably, the selective V 1a R agonist POV led to a reduction of cumulative net fluid balance as compared with NE animals despite similar central venous pressures and pulmonary arterial occlusion pressures. In conjunction with the higher plasma protein levels in the POV than in the NE group, these findings potentially indicate a reduction in vascular leakage by POV. This assumption is supported by an experimental study in rats demonstrating that platelet activating factorinduced vascular leak is reversed by a selective V 1a R agonist and only attenuated by AVP (26) . The relevance of V 1a R selectivity is further emphasized by an ovine model of pneumonia-induced sepsis showing that vascular leakage is promoted by V 2 R stimulation (6) . In this context, it needs to be considered that there were no differences in the infused volumes among groups in the present study. As a result of the absence of a well-defined "gold standard" for the assessment of vascular leakage, however, no definite conclusion concerning this finding in the context of the disease can be drawn.
In addition to the attenuation in cardiovascular dysfunction, POV was associated with an improvement in pulmonary function as indicated by higher PaO 2 /FIO 2 ratios compared with the AVP and NE group. This finding may be explained by an increased venous admixture resulting from an improved global oxygen transport as well as by reductions in vascular leakage and nitrosative stress (lower concentrations of 3-nitrotyrosine and higher tissue levels of hemeoxygenase-1 in the lung of POV-treated animals vs. the AVP or NE group). Whereas 3-nitrotyrosine represents a stable in vivo biomarker of the highly cytotoxic compound peroxynitrite (27) , hemeoxygenase-1 has been reported to provide cytoprotective effects (28) . The pivotal role of oxidative and nitrosative stress in the pathogenesis of acute lung injury has been suggested in numerous experimental studies (29, 30) .
In agreement with previous reports (31, 32) , AVP and the selective V 1a R agonist POV improved renal function, as evidenced by the increased creatinine clearance and urine output as compared with NE animals. These findings may be explained by the V 1a R-mediated selective vasoconstriction in efferent glomerular arterioles and the subsequent increase in glomerular filtration pressure (33) .
Stabilization of cardiovascular, pulmonary, and renal function in response to first-line therapy with the highly selective V 1a R agonist POV led to a slight prolongation in survival time as compared with AVP and sole NE treatment. Such effects were not observed with AVP, suggesting these beneficial effects were related to the V 1a R selective effects. This study has some limitations that we want to acknowledge. In the absence of source control, the present model was associated with a high mortality rate. Therefore, the therapeutic approaches could only be analyzed during the acute injury. For this reason, differences in survival time in the current study should not be overestimated. Because V 1a Rs are involved in the regulation of glucose, fat, and protein metabolism (34) as well as the immune system (35) , further studies are warranted to determine the metabolic and immune-modulating effects of selective V 1a R agonists in the treatment of septic shock. In addition, interpretation of the current data is limited by the use of previously healthy animals, whereas the majority of patients typically suffer from comorbidities. Finally, the risk of falsepositive results in a study with numerous outcome variables and time points has to be taken into consideration.
CONCLUSIONS
In summary, this is the first study providing evidence that first-line treatment with the highly selective V 1a R agonist POV supplemented with open-label NE improves vascular, pulmonary, and renal function, increases oxygen delivery, and slightly prolongs survival as compared with first-line AVP or standard treatment with NE in ovine septic shock. Based on the present findings, the use of selective V 1a R agonists appears to be superior to unselective vasopressin analogs and standard treatment with single NE in septic shock. 
